Hamostaseologie 2020; 40(04): 509-514
DOI: 10.1055/a-1200-0417
Review Article

Usefulness of Thrombin Generation

Armando Tripodi
1   IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
› Author Affiliations

Abstract

Thrombin generation (TG) is a global coagulation procedure meant to continuously monitor thrombin formation and decay upon exposure of platelet-poor plasma to exogenous triggers such as tissue factor, phospholipids, and calcium chloride. The procedure can also be performed in platelet-rich plasma by omitting exogenous phospholipids. TG is thought to mimic more than other coagulation procedures the process that occurs in vivo. Over the years, TG has been used to investigate coagulation mechanisms, which were not completely understood, or to investigate hyper- or hypocoagulability in clinical conditions known to be at increased risk of thrombosis or hemorrhage, respectively. More recently, TG has been employed as a laboratory tool to assess the risk of recurrent venous thromboembolism or to assess the risk of arterial thromboembolism in specific clinical settings or in the general population. The article reviews the value and limitations of TG.



Publication History

Received: 04 May 2020

Accepted: 15 June 2020

Article published online:
30 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 
  • References

  • 1 Garcia JG, Pavalko FM, Patterson CE. Vascular endothelial cell activation and permeability responses to thrombin. Blood Coagul Fibrinolysis 1995; 6 (07) 609-626
  • 2 Siller-Matula JM, Schwameis M, Blann A, Mannhalter C, Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost 2011; 106 (06) 1020-1033
  • 3 Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21 (05) 1238-1247
  • 4 Bitto N, Liguori E, La Mura V. Coagulation, microenvironment and liver fibrosis. Cells 2018; 7 (08) 85
  • 5 MacFarlane RG, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol 1953; 6 (01) 3-8
  • 6 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56 (01) 9-17
  • 7 Tripodi A. The history of phenotypic testing in thrombosis and hemostasis. Semin Thromb Hemost 2008; 34 (07) 585-592
  • 8 Douxfils J, Morimont L, Bouvy C. et al. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost 2019; 17 (08) 1273-1287
  • 9 Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 2012; 58 (08) 1252-1259
  • 10 de Laat-Kremers RMW, Ninivaggi M, Devreese KMJ, de Laat B. Towards standardization of thrombin generation assays: inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey. J Thromb Haemost 2020; (e-pub ahead of print) DOI: 10.1111/jth.14863.
  • 11 Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 88 (05) 547-554
  • 12 Tripodi A, Primignani M, Chantarangkul V. et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44 (02) 440-445
  • 13 Tripodi A. Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. Thromb Haemost 2017; 117 (05) 830-836
  • 14 Curvers J, Thomassen MC, Nicolaes GA. et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105 (01) 88-94
  • 15 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2 (11) 1954-1959
  • 16 Tripodi A, Chantarangkul V, Mancuso ME, Lemma L, Clerici M, Santagostino E. Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents. J Thromb Haemost 2012; 10 (04) 716-719
  • 17 Dargaud Y, Luddington R, Gray E. et al. Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125 (04) 353-356
  • 18 Tripodi A, Branchi A, Chantarangkul V. et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 2011; 31 (02) 165-172
  • 19 Tripodi A, Primignani M, Badiali S. et al. Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. J Thromb Thrombolysis 2019; 48 (01) 52-60
  • 20 Tripodi A, Ammollo CT, Semeraro F. et al. Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine 2017; 56 (02) 298-307
  • 21 Tripodi A, Fracanzani AL, Chantarangkul V, Primignani M, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 2017; 66 (01) 248-250
  • 22 Potze W, Siddiqui MS, Boyett SL. et al. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol 2016; 65 (05) 980-987
  • 23 Saibeni S, Saladino V, Chantarangkul V. et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010; 125 (03) 278-282
  • 24 Tripodi A, Salerno F, Chantarangkul V. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (03) 553-558
  • 25 Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8 (09) 1994-2000
  • 26 Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing concepts of cirrhotic coagulopathy. Am J Gastroenterol 2017; 112 (02) 274-281
  • 27 Miyawaki Y, Suzuki A, Fujita J. et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366 (25) 2390-2396
  • 28 Zekavat OR, Haghpanah S, Dehghani J, Afrasiabi A, Peyvandi F, Karimi M. Comparison of thrombin generation assay with conventional coagulation tests in evaluation of bleeding risk in patients with rare bleeding disorders. Clin Appl Thromb Hemost 2014; 20 (06) 637-644
  • 29 Tran HT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Andre Holme P. Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia 2015; 21 (02) 275-283
  • 30 Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103 (04) e181-e183
  • 31 Palareti G, Cosmi B, Legnani C. et al; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355 (17) 1780-1789
  • 32 Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6 (08) 1327-1333
  • 33 van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. J Thromb Haemost 2015; 13 (09) 1642-1652
  • 34 Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008; 54 (12) 2042-2048
  • 35 Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 2015; 135 (06) 1186-1190
  • 36 Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104 (12) 3631-3634
  • 37 Smid M, Dielis AW, Winkens M. et al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011; 9 (03) 450-456
  • 38 van Paridon PCS, Panova-Noeva M, van Oerle R. et al. Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. Haematologica 2019; (e-pub ahead of print) DOI: 10.3324/haematol.2019.221655.